The Coalition for Epidemic Preparedness Innovation (CEPI), the Global Alliance for Vaccines and Immunization (GAVI) and the World Health Organization have released the first interim forecast of COVID-19 vaccine distribution worldwide as part of the COVAX Initiative (PDF).
The forecast contains information about the indicative distribution:
- 240 million doses of AstraZeneca / Oxford vaccine licensed by Serum Institute of India (SII) - AZ / SII;
- 96 million doses of AstraZeneca / Oxford vaccine - AZ;
- 1.2 million doses of Pfizer-BioNTech vaccine.
The Pfizer-BioNTech vaccine will be distributed in Q1 this year, and the AstraZeneca / Oxford vaccine in H1 of the year.
Uzbekistan, according to published data, will receive 2.64 million doses of AZ / SII vaccine.
Data on the distribution of drugs in post-Soviet countries:
- Azerbaijan - 506 400 AZ;
- Armenia - 146,400 AZ;
- Georgia - 184800 AZ and 29250 Pfizer-BioNTech;
- Kyrgyzstan - 504,000 AZ / SII;
- Moldova - 156,000 AZ;
- Tajikistan - 732,000 AZ / SII;
- Ukraine - 2,215,200 AZ and 117,000 Pfizer-BioNTech.
The vaccine manufacturers are expected to start shipping in late February. On average, the first phase of COVAX drug distribution will vaccinate 3.3% of the population in 145 countries. This, experts believe, will be enough to protect the most vulnerable groups, including health workers.
Since December last year, the third stage of clinical trials of a vaccine from the Chinese Zhifei Longcom Biopharmaceutical has been underway in Uzbekistan. If successful, the country will be eligible to purchase the vaccine at a reduced price. In addition, the Russian Direct Investment Fund reported that it had agreed to supply up to 35 million doses of Sputnik V vaccine to Uzbekistan. In January, Deputy Health Minister Bakhodir Yusupaliev announced that 100,000 doses of Pfizer-BioNTech vaccine would be supplied to the country.
